【ChiCTR2300072788】Effects of a multicomponent intervention on functional ability in community-dwelling older people: a randomized controlled trial
ChiCTR2300072788
尚未开始
/
/
/
2023-06-25
/
/
Functional ability
Effects of a multicomponent intervention on functional ability in community-dwelling older people: a randomized controlled trial
Effects of a multicomponent intervention on functional ability in community-dwelling older people: a randomized controlled trial
To conduct a 12-week group-based multicomponent intervention for 300 persons aged 60 years or older to improve functional ability, and to promote healthy ageing.
随机平行对照
其它
To obtain an adequate sample size, community centres under the eHealth project with the largest number of participants who have orare at risk of sarcopenia will be selected. Fifteen centres will be randomly selected and allocated to either group 1(receiving the multicomponent intervention without goal-setting), group 2 (receiving the multicomponent intervention with goal-setting), or group 3 (receiving the HLE program). We choose cluster RCT because randomization at the cluster (centre) level will reduce the likelihood of experimental contamination. Group 1 - receiving the multicomponent intervention without goal-setting. Group 2 - receiving the multicomponent intervention with goal-setting. Group 3 - receiving the HLE program.
Not stated
The Hong Kong Jockey Club Charities Trust
/
100
/
2023-07-01
2024-06-30
/
1. Community-dwelling older men or women aged 60 years and older; 2. Understand Cantonese; 3. With limited mobility without mobility disability (Short Physical Performance Battery score = 3-9); 4. Assessed with possible sarcopenia (low muscle strength (handgrip strength M: < 28 kg, F: < 18 kg) or low physical performance (5-chair rise test >= 12 s)); 5. Diagonised with sarcopenia (low appendicular skeletal muscle mass (bioelectrical impedance analysis M: < 7.0kg/m2, F: < 5.7kg/m2) and low muscle strength (handgrip strength M: < 28 kg, F: < 18 kg) and/or low physical performance (5-chair rise test >= 12 s)); 6. With history of falls in the past year; 7. With physical pre-frailty/frailty (FRAIL score >= 1); 8. With cognitive impairment (Montreal Cognitive Assessment 5-Minute Protocol Hong Kong Version score <= age and education corrected percentile cutoff, without doctor diagnosed dementia); 9. With impaired vitality (Mini Nutritional Assessment Short-Form score <= 11/low muscle strength (handgrip strength M: < 28 kg, F: < 18 kg).;
请登录查看1. Unable to get up from a chair (with or without using the armrests) and stand for 20 seconds; 2. Receive treatment for medical conditions that preclude physical activity; 3. Diagnosis of dementia, dementia suspected by a clinician, or terminal illness; 4. Interviewer-adjudicated severe visual or hearing impairment; 5. Participation in a structured physical activity program, nutritional activities or board game activities; 6. Contraindications to safely engage in trial activities as judged by health professionals (e.g., doctors, nurses, physiotherapists etc.).;
请登录查看The Hong Kong Jockey Club Charities Trust
/
The Hong Kong Jockey Club Charities Trust的其他临床试验
- Effects of a multicomponent intervention on functional ability in community-dwelling older people: a randomized controlled trial
- Effectiveness of post hospital discharge support program to improve the well-being of people with dementia and family caregivers
- Unpacking the concept of physical literacy to support children's physical literacy journey: a parent-focused intervention
- Effectiveness of a dementia friendly program and bluetooth tracking technology to enhance public knowledge and attitude on dementia and reduce caregiver anxiety on getting lost
CUHK Jockey Club Institute of Ageing的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示:#脐带间充质干细胞(#hUC-MSCs)
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点,索弗度肽(survodutide)成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构:国家卫生健康委办公厅、 2026-11-10
-
颁布机构:国家卫健委(原国家卫计委) 2026-11-10
-
颁布机构:国家药品审评中心(CDE) 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构:国家市场监督管理总局 2026-11-07
-
颁布机构:国家市场监督管理总局 2026-11-07
-
颁布机构:国家市场监督管理总局 2026-11-04

